Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Homo sapiens

ABSTRACT: LncRNAs specific signature in acute myeloid leukemia with intermediate risk

PROVIDER: PRJNA265845 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR1635300_1.fastq.gz	Fastqsanger.gz
	SRR1635300_2.fastq.gz	Fastqsanger.gz
	SRR1635310_1.fastq.gz	Fastqsanger.gz
	SRR1635310_2.fastq.gz	Fastqsanger.gz
	SRR1635320_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 80

Similar Datasets

Homo sapiens

Project description:Expression and Prognostic impact of LncRNAs in Acute Myeloid Leukemia

| PRJNA268523 | ENA

Homo sapiens

Project description:acute myeloid leukemia (AML)

| PRJNA87151 | ENA

Homo sapiens

Project description:Acute myeloid leukemia study

| PRJNA84991 | ENA

Homo sapiens

Project description:acute myeloid leukemia (AML)

| PRJNA87153 | ENA

Homo sapiens

Project description:Chronic growth factor signaling in Acute Myeloid Leukemia is connected to a specific chromatin signature [Agilent]

| PRJNA272429 | ENA

Homo sapiens

Project description:Chronic growth factor signaling in Acute Myeloid Leukemia is connected to a specific chromatin signature [Methylation]

| PRJNA272531 | ENA

Homo sapiens

Project description:Chronic growth factor signaling in Acute Myeloid Leukemia is connected to a specific chromatin signature [ChIP-Seq]

| PRJNA272428 | ENA

Homo sapiens

Project description:Chronic growth factor signaling in Acute Myeloid Leukemia is connected to a specific chromatin signature [DNAse-Seq]

| PRJNA272427 | ENA

Homo sapiens

Project description:TARGET: Acute Myeloid Leukemia (AML)

| PRJNA89525 | ENA

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

Project description:This is a first-in-human, multi-center, open-label clinical study with separate dose escalation (Phase 1) and expansion (Phase 2) stages to assess preliminary safety, tolerability, and efficacy of the second generation oral XPO1 inhibitor KPT-8602 in participants with relapsed/refractory multiple myeloma (MM), metastatic colorectal cancer (mCRC), metastatic castration resistant prostate cancer (mCRPC), higher risk myelodysplastic syndrome (HRMDS), acute myeloid leukemia (AML) and newly diagnosed intermediate/high-risk MDS. Dose escalation and dose expansion may be included for all parts of the study as determined by ongoing study results.

| 2205768 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data